 Bradley Corr
Concepts (186)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Endometrial Neoplasms | 16 | 2025 | 162 | 5.040 |
Why?
| | Ovarian Neoplasms | 11 | 2025 | 484 | 2.400 |
Why?
| | Carcinoma, Endometrioid | 3 | 2022 | 44 | 1.880 |
Why?
| | beta Catenin | 4 | 2023 | 225 | 1.390 |
Why?
| | Lymph Nodes | 2 | 2018 | 472 | 0.920 |
Why?
| | Neoplasm Recurrence, Local | 5 | 2025 | 958 | 0.910 |
Why?
| | Uterine Cervical Neoplasms | 6 | 2024 | 230 | 0.890 |
Why?
| | Wnt Signaling Pathway | 2 | 2021 | 170 | 0.790 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 9 | 2025 | 1560 | 0.780 |
Why?
| | Wnt Proteins | 1 | 2021 | 127 | 0.680 |
Why?
| | Tumor Suppressor Protein p53 | 5 | 2025 | 507 | 0.640 |
Why?
| | Mutation | 5 | 2023 | 3717 | 0.620 |
Why?
| | Antibodies, Monoclonal, Humanized | 4 | 2024 | 757 | 0.590 |
Why?
| | Adenocarcinoma, Mucinous | 1 | 2018 | 73 | 0.540 |
Why?
| | Gynecologic Surgical Procedures | 2 | 2020 | 57 | 0.520 |
Why?
| | Venous Thromboembolism | 2 | 2020 | 287 | 0.490 |
Why?
| | Neoplasms, Glandular and Epithelial | 1 | 2015 | 35 | 0.490 |
Why?
| | Keratin-5 | 1 | 2015 | 50 | 0.480 |
Why?
| | Cisplatin | 2 | 2023 | 299 | 0.470 |
Why?
| | Hysterectomy | 4 | 2019 | 118 | 0.460 |
Why?
| | Antineoplastic Agents | 4 | 2023 | 2046 | 0.420 |
Why?
| | Bile Ducts, Intrahepatic | 1 | 2013 | 65 | 0.420 |
Why?
| | Female | 38 | 2025 | 68734 | 0.420 |
Why?
| | Immunoconjugates | 2 | 2024 | 104 | 0.410 |
Why?
| | Neoplasm Grading | 4 | 2025 | 282 | 0.410 |
Why?
| | Cholangiocarcinoma | 1 | 2013 | 77 | 0.410 |
Why?
| | Camptothecin | 2 | 2024 | 110 | 0.400 |
Why?
| | Aged, 80 and over | 17 | 2025 | 7052 | 0.400 |
Why?
| | Bile Duct Neoplasms | 1 | 2013 | 99 | 0.400 |
Why?
| | Genital Neoplasms, Female | 3 | 2024 | 82 | 0.370 |
Why?
| | Lymph Node Excision | 3 | 2018 | 164 | 0.360 |
Why?
| | Drug Resistance, Neoplasm | 5 | 2025 | 752 | 0.360 |
Why?
| | Middle Aged | 25 | 2025 | 31136 | 0.350 |
Why?
| | Molecular Targeted Therapy | 2 | 2025 | 391 | 0.340 |
Why?
| | Biomarkers, Tumor | 4 | 2023 | 1164 | 0.330 |
Why?
| | Humans | 40 | 2025 | 129626 | 0.300 |
Why?
| | Aged | 21 | 2025 | 22061 | 0.300 |
Why?
| | Maytansine | 2 | 2025 | 16 | 0.290 |
Why?
| | Phenylurea Compounds | 2 | 2025 | 88 | 0.270 |
Why?
| | Bevacizumab | 3 | 2025 | 128 | 0.270 |
Why?
| | Quinolines | 2 | 2025 | 156 | 0.260 |
Why?
| | Immunohistochemistry | 2 | 2023 | 1685 | 0.250 |
Why?
| | Cell Survival | 2 | 2021 | 1076 | 0.240 |
Why?
| | Cell Line, Tumor | 4 | 2024 | 3186 | 0.240 |
Why?
| | Immunotherapy | 2 | 2024 | 596 | 0.240 |
Why?
| | Folate Receptor 1 | 1 | 2024 | 15 | 0.230 |
Why?
| | Adult | 19 | 2025 | 35599 | 0.220 |
Why?
| | Tryptophan Oxygenase | 1 | 2024 | 34 | 0.220 |
Why?
| | Poly-ADP-Ribose Binding Proteins | 2 | 2023 | 33 | 0.210 |
Why?
| | DNA Polymerase II | 2 | 2023 | 38 | 0.210 |
Why?
| | Tertiary Care Centers | 1 | 2023 | 148 | 0.200 |
Why?
| | Neoplasms | 3 | 2022 | 2455 | 0.200 |
Why?
| | Fallopian Tube Neoplasms | 1 | 2022 | 15 | 0.190 |
Why?
| | Retrospective Studies | 7 | 2025 | 14522 | 0.190 |
Why?
| | Thrombocytopenia | 1 | 2023 | 186 | 0.180 |
Why?
| | Heterocyclic Compounds, 3-Ring | 1 | 2021 | 31 | 0.180 |
Why?
| | Precision Medicine | 1 | 2025 | 387 | 0.180 |
Why?
| | Indazoles | 1 | 2021 | 66 | 0.180 |
Why?
| | Neoplasm Staging | 3 | 2019 | 1282 | 0.170 |
Why?
| | Clinical Trials, Phase I as Topic | 1 | 2020 | 51 | 0.170 |
Why?
| | Benzoxazoles | 1 | 2020 | 20 | 0.170 |
Why?
| | Machine Learning | 1 | 2025 | 443 | 0.170 |
Why?
| | High-Throughput Nucleotide Sequencing | 1 | 2023 | 487 | 0.170 |
Why?
| | Imidazoles | 1 | 2021 | 234 | 0.170 |
Why?
| | Azepines | 1 | 2020 | 88 | 0.160 |
Why?
| | Mindfulness | 1 | 2021 | 116 | 0.160 |
Why?
| | Enoxaparin | 1 | 2020 | 59 | 0.160 |
Why?
| | Disease Susceptibility | 1 | 2021 | 334 | 0.160 |
Why?
| | Microsatellite Instability | 1 | 2019 | 37 | 0.160 |
Why?
| | Survival Analysis | 3 | 2020 | 1269 | 0.150 |
Why?
| | Class I Phosphatidylinositol 3-Kinases | 1 | 2019 | 81 | 0.150 |
Why?
| | Margins of Excision | 1 | 2019 | 38 | 0.150 |
Why?
| | Pyridones | 1 | 2020 | 158 | 0.150 |
Why?
| | Gene Expression Regulation, Neoplastic | 2 | 2021 | 1336 | 0.150 |
Why?
| | Protein Kinase Inhibitors | 2 | 2023 | 887 | 0.140 |
Why?
| | Oncologists | 1 | 2018 | 35 | 0.140 |
Why?
| | Recurrence | 1 | 2021 | 1011 | 0.140 |
Why?
| | Frozen Sections | 1 | 2018 | 26 | 0.140 |
Why?
| | Cross-Sectional Studies | 3 | 2018 | 5075 | 0.140 |
Why?
| | PTEN Phosphohydrolase | 1 | 2019 | 161 | 0.140 |
Why?
| | Preoperative Care | 2 | 2017 | 338 | 0.140 |
Why?
| | Pyridines | 1 | 2021 | 478 | 0.140 |
Why?
| | Cohort Studies | 4 | 2025 | 5426 | 0.140 |
Why?
| | Disease Management | 1 | 2021 | 588 | 0.140 |
Why?
| | Pyrazoles | 1 | 2020 | 404 | 0.130 |
Why?
| | Pyrimidines | 1 | 2020 | 459 | 0.130 |
Why?
| | Amyotrophic Lateral Sclerosis | 3 | 2003 | 68 | 0.130 |
Why?
| | Minority Groups | 1 | 2018 | 249 | 0.130 |
Why?
| | Tissue Array Analysis | 1 | 2015 | 55 | 0.120 |
Why?
| | Gynecology | 1 | 2018 | 174 | 0.120 |
Why?
| | Anticoagulants | 1 | 2020 | 637 | 0.120 |
Why?
| | Perioperative Period | 1 | 2015 | 49 | 0.120 |
Why?
| | Neoplasm Invasiveness | 1 | 2017 | 481 | 0.120 |
Why?
| | Radiography, Thoracic | 1 | 2016 | 166 | 0.120 |
Why?
| | Laparotomy | 1 | 2015 | 106 | 0.110 |
Why?
| | Surgeons | 1 | 2018 | 264 | 0.110 |
Why?
| | DNA Mismatch Repair | 2 | 2025 | 47 | 0.110 |
Why?
| | Disease Models, Animal | 1 | 2024 | 4078 | 0.110 |
Why?
| | Heparin | 1 | 2015 | 254 | 0.110 |
Why?
| | Quality of Health Care | 1 | 2018 | 604 | 0.110 |
Why?
| | Treatment Outcome | 3 | 2020 | 10219 | 0.110 |
Why?
| | Platinum | 2 | 2025 | 44 | 0.110 |
Why?
| | Robotic Surgical Procedures | 1 | 2015 | 115 | 0.100 |
Why?
| | Receptors, Estrogen | 1 | 2015 | 422 | 0.100 |
Why?
| | Membrane Proteins | 1 | 2019 | 1125 | 0.100 |
Why?
| | Paclitaxel | 2 | 2025 | 217 | 0.100 |
Why?
| | Combined Modality Therapy | 2 | 2013 | 1203 | 0.100 |
Why?
| | Ovary | 1 | 2013 | 209 | 0.090 |
Why?
| | Prognosis | 5 | 2023 | 3774 | 0.090 |
Why?
| | Breast Neoplasms | 1 | 2024 | 2133 | 0.090 |
Why?
| | Postoperative Complications | 2 | 2020 | 2477 | 0.090 |
Why?
| | Case-Control Studies | 1 | 2019 | 3378 | 0.090 |
Why?
| | Maximum Tolerated Dose | 2 | 2022 | 193 | 0.090 |
Why?
| | Chemoradiotherapy | 2 | 2025 | 208 | 0.090 |
Why?
| | Prospective Studies | 4 | 2023 | 7135 | 0.090 |
Why?
| | Tumor Microenvironment | 2 | 2024 | 627 | 0.080 |
Why?
| | Cell Proliferation | 1 | 2015 | 2373 | 0.070 |
Why?
| | Young Adult | 5 | 2025 | 12455 | 0.070 |
Why?
| | Apoptosis | 1 | 2015 | 2492 | 0.070 |
Why?
| | Retreatment | 1 | 2025 | 70 | 0.060 |
Why?
| | GPI-Linked Proteins | 1 | 2025 | 68 | 0.060 |
Why?
| | Carboplatin | 1 | 2025 | 139 | 0.060 |
Why?
| | Carbonyl Reductase (NADPH) | 1 | 2024 | 5 | 0.060 |
Why?
| | Wnt4 Protein | 1 | 2024 | 18 | 0.050 |
Why?
| | Cell Adhesion Molecules | 1 | 2024 | 173 | 0.050 |
Why?
| | Disease-Free Survival | 1 | 2025 | 646 | 0.050 |
Why?
| | Kynurenine | 1 | 2024 | 113 | 0.050 |
Why?
| | Registries | 3 | 2018 | 1899 | 0.050 |
Why?
| | Lung Neoplasms | 1 | 2016 | 2342 | 0.050 |
Why?
| | Mesylates | 1 | 2022 | 7 | 0.050 |
Why?
| | Topoisomerase I Inhibitors | 1 | 2022 | 16 | 0.050 |
Why?
| | Tryptophan | 1 | 2024 | 177 | 0.050 |
Why?
| | AMP-Activated Protein Kinases | 1 | 2024 | 191 | 0.050 |
Why?
| | B7-H1 Antigen | 1 | 2024 | 198 | 0.050 |
Why?
| | Antigens, Neoplasm | 1 | 2024 | 308 | 0.050 |
Why?
| | Ligands | 1 | 2024 | 621 | 0.050 |
Why?
| | Ambulatory Care Facilities | 1 | 2003 | 226 | 0.050 |
Why?
| | Antibodies, Bispecific | 1 | 2022 | 49 | 0.050 |
Why?
| | Adolescent | 4 | 2021 | 20412 | 0.040 |
Why?
| | Enzyme Inhibitors | 1 | 2024 | 827 | 0.040 |
Why?
| | Decision Trees | 1 | 2000 | 90 | 0.040 |
Why?
| | Aurora Kinase A | 1 | 2020 | 54 | 0.040 |
Why?
| | Mechanistic Target of Rapamycin Complex 2 | 1 | 2020 | 62 | 0.040 |
Why?
| | Interleukin-6 | 1 | 2024 | 723 | 0.040 |
Why?
| | Mechanistic Target of Rapamycin Complex 1 | 1 | 2020 | 119 | 0.040 |
Why?
| | Vascular Endothelial Growth Factor A | 1 | 2022 | 530 | 0.040 |
Why?
| | Patient Care Team | 1 | 2003 | 600 | 0.040 |
Why?
| | Neoplasm Metastasis | 1 | 2020 | 611 | 0.040 |
Why?
| | Ireland | 3 | 2003 | 27 | 0.030 |
Why?
| | Xenograft Model Antitumor Assays | 1 | 2020 | 808 | 0.030 |
Why?
| | Program Evaluation | 1 | 2021 | 875 | 0.030 |
Why?
| | Macrophages | 1 | 2024 | 1488 | 0.030 |
Why?
| | Regression Analysis | 1 | 2019 | 997 | 0.030 |
Why?
| | Neoadjuvant Therapy | 1 | 2018 | 379 | 0.030 |
Why?
| | Disease Progression | 2 | 2020 | 2627 | 0.030 |
Why?
| | RNA | 1 | 2022 | 882 | 0.030 |
Why?
| | Ileus | 1 | 2015 | 12 | 0.030 |
Why?
| | Salpingectomy | 1 | 2015 | 13 | 0.030 |
Why?
| | Urinary Retention | 1 | 2015 | 20 | 0.030 |
Why?
| | Caregivers | 1 | 2021 | 806 | 0.030 |
Why?
| | Blood Loss, Surgical | 1 | 2015 | 93 | 0.030 |
Why?
| | Ovariectomy | 1 | 2015 | 135 | 0.030 |
Why?
| | Survival Rate | 1 | 2019 | 1872 | 0.030 |
Why?
| | Pelvis | 1 | 2015 | 104 | 0.030 |
Why?
| | Logistic Models | 1 | 2018 | 1986 | 0.030 |
Why?
| | Pandemics | 1 | 2021 | 1491 | 0.030 |
Why?
| | Patient Readmission | 1 | 2018 | 653 | 0.030 |
Why?
| | Referral and Consultation | 1 | 2018 | 730 | 0.030 |
Why?
| | Follow-Up Studies | 2 | 2018 | 4894 | 0.030 |
Why?
| | United States | 2 | 2019 | 13871 | 0.020 |
Why?
| | Signal Transduction | 1 | 2024 | 4931 | 0.020 |
Why?
| | Animals | 2 | 2024 | 35391 | 0.020 |
Why?
| | Practice Patterns, Physicians' | 1 | 2018 | 1271 | 0.020 |
Why?
| | Length of Stay | 1 | 2015 | 1122 | 0.020 |
Why?
| | Immunotherapy, Adoptive | 1 | 2012 | 300 | 0.020 |
Why?
| | Patient Discharge | 1 | 2015 | 836 | 0.020 |
Why?
| | Quality of Life | 1 | 2020 | 2688 | 0.020 |
Why?
| | Age Factors | 1 | 2015 | 3152 | 0.020 |
Why?
| | Diagnosis, Differential | 2 | 2003 | 1432 | 0.020 |
Why?
| | Antibodies, Monoclonal | 1 | 2012 | 1366 | 0.020 |
Why?
| | Mice | 1 | 2020 | 16961 | 0.010 |
Why?
| | Male | 4 | 2020 | 63670 | 0.010 |
Why?
| | Interprofessional Relations | 1 | 2003 | 277 | 0.010 |
Why?
| | Central Nervous System Diseases | 1 | 2000 | 69 | 0.010 |
Why?
| | Age of Onset | 1 | 2000 | 495 | 0.010 |
Why?
| | Palliative Care | 1 | 2003 | 702 | 0.010 |
Why?
|
|
Corr's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|